Patients admitted to intensive care units (ICU) are at high risk of developing secondary infections, and this is in part due to dysfunction or failure of their 'germ killing' functions (the immune system). Our group has recently identified three signatures of immune system failure which can be readily detected on a blood sample, and importantly, appear to predict the chances of developing secondary infection. Such a test would have major benefits for the management of patients in intensive care if it can be translated into a test usable in everyday clinical practice. This study aims to validate our original findings in a cohort of patients from multiple ICUs, using a test which will be suitable for everyday clinical practice, and thus take the next step towards developing a market-ready test. Study hypothesis: Measurement of neutrophil CD88, monocyte HLA-DR and percentage Tregs will accurately predict the risk of nosocomial infection.
Study Type
OBSERVATIONAL
Enrollment
168
Royal Infirmary of Edinburgh
Edinburgh, United Kingdom
Western General Hospital
Edinburgh, United Kingdom
St Thomas' Hospital
London, United Kingdom
Sunderland Royal Hospital
Sunderland, United Kingdom
The development of immune dysfunction (see below) and its association with ICU-acquired infection within the 16 day study period.
Time frame: Within the first 16 days
ICU Outcome (lived/died)
Time frame: Within first 16 days
Death from sepsis
Time frame: Within first 16 days
Organ dysfunction as determined by SOFA score
Time frame: Within first 14 days
Length of ICU stay
Time frame: Up to 3 months (for current hospital admission only)
Duration of organ support in ICU
Time frame: Within first 14 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.